Eyetech Pharmaceuticals, OSI ophthalmic, drug delivery, cancer news

OSIP said that before it closes its proposed $935 million acquisition of EYET, it wants to assess the possible impact of Phase III data for Lucentis ranibizumab that were released by Genentech Inc. (...